GlassScriptPhysician profile
Samuel O Ani
NPI 1417199605
$2,647.00
in general payments reported to CMS, 2019-2025
20 companies · $648 in 2025
The $648 reported for 2025 was more than what 92% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $243 · 2023: $770 · 2024: $985 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,403.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $622.49 | 2022-2024 | Xarelto |
| Shionogi INC | $377.37 | 2022-2025 | Fetroja |
| Merck Sharp & Dohme LLC | $348.23 | 2022-2025 | Zerbaxa, Recarbrio, Dificid |
| Melinta Therapeutics, LLC | $347.09 | 2022-2025 | Kimyrsa, Orbactiv, Rezzayo |
| Gilead Sciences, INC. | $251.91 | 2023-2025 | Yeztugo |
| Abbott Laboratories | $140.76 | 2024 | Optis |
| Pfizer INC. | $130.88 | 2022-2024 | |
| La Jolla Pharmaceutical Company | $65.53 | 2023-2025 | Xerava, Xacduro |
| Astellas Pharma US INC | $54.18 | 2023-2024 | Veozah |
| Bioxcel Therapeutics, INC. | $52.46 | 2023 | Igalmi |
| Genzyme Corporation | $36.17 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.92 | 2025 | Jardiance |
| Insmed, INC. | $30.21 | 2025 | Arikayce |
| Cumberland Pharmaceuticals, INC. | $29.22 | 2023-2025 | Caldolor |
| Phathom Pharmaceuticals, INC. | $26.63 | 2024 | Voquezna |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Reprise Biomedical, INC. | $23.46 | 2023 | Miro3d |
| Fisher Scientific Company L.L.C. | $21.29 | 2024 | Procalcitonin |
| Amgen INC. | $20.18 | 2024 | Repatha |
| Aytu Biopharma, INC. | $17.07 | 2025 | |
| Chiesi USA, INC. | $16.95 | 2025 | Cleviprex, Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Ani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.